Heart Attack Treatment: New Studies Challenge Conventional Wisdom
Two groundbreaking studies presented at TCT 2025 are shaking up how we approach heart attacks, particularly the most severe type, ST-elevation myocardial infarction (STEMI), and a puzzling variant called myocardial infarction with nonobstructive coronary arteries (MINOCA). But here's where it gets controversial: these studies suggest that our current strategies might not always be the best approach.
iMODERN Trial: Timing is Everything (or is it?)
The iMODERN trial, published simultaneously in the prestigious New England Journal of Medicine, tackled a crucial question: should we immediately treat all narrowed arteries during a STEMI, even those not directly causing the attack, or wait and see if they need intervention later? Researchers divided 1,146 STEMI patients with at least one non-culprit lesion into two groups. One group received immediate treatment guided by a technique called instantaneous wave-free ratio (iFR), while the other waited for a cardiac stress MRI to determine if treatment was necessary.
Surprisingly, after three years, there was no significant difference in outcomes like death, recurrent heart attacks, or heart failure hospitalizations between the two groups. This challenges the long-held belief that immediate treatment of all narrowed arteries is always superior. And this is the part most people miss: the study also found a slightly higher rate of serious adverse events in the immediate treatment group, raising questions about the risks versus benefits of this approach.
PROMISE Trial: Unraveling the MINOCA Mystery
MINOCA, a heart attack without obvious blockage, has long baffled doctors. The PROMISE trial took a novel approach, using advanced diagnostics to pinpoint the underlying cause of MINOCA in each patient and tailoring treatment accordingly. This personalized strategy led to significant improvements in chest pain (angina) after 12 months compared to standard care, which typically involves just angiography and standard heart attack treatment.
Dr. Rocco A. Montone, presenting the findings, emphasized the safety and diagnostic power of this approach, with 75.5% of cases requiring a change in their initial diagnosis. While the trial had limitations, including early termination due to its open-label design, it offers a promising new direction for treating this enigmatic condition.
Food for Thought: Rethinking Heart Attack Treatment
These studies raise important questions. Should we be more selective about treating non-culprit lesions in STEMI patients? Is personalized medicine the future of MINOCA treatment? The iMODERN trial's findings, in particular, are likely to spark debate. While immediate treatment might seem intuitively better, the data suggests a more nuanced approach is needed. What do you think? Should we prioritize immediate intervention or a more cautious, personalized strategy? Let us know your thoughts in the comments below.
For more in-depth coverage of these groundbreaking studies, visit the TCT 2025 Meeting Coverage on the American College of Cardiology website: https://www.acc.org/Latest-in-Cardiology/Features/Meeting-Coverage/2025/TCT-2025-meeting-coverage
Keywords: Transcatheter Cardiovascular Therapeutics, TCT25, Angiography, Acute Coronary Syndrome, STEMI, MINOCA, iFR, Cardiac MRI, Personalized Medicine
